Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

NCT03647878 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03647878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03647878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
Lead sponsor
Ipsen
Phase
Observational
Overall status
Active, not recruiting
Start date
September 24, 2018
Completion date
September 30, 2027
Enrollment
224 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, metastatic renal cell carcinoma